Chondroitin Sulphate Efficay/Safety in Patients With Knee Osteoarthritis and Psoriasis
Phase 4
Completed
- Conditions
- OsteoarthritisPsoriasisJoint DiseasesMuskuloskeletal DiseasesSkin Diseases
- Interventions
- Drug: Placebo
- Registration Number
- NCT00669123
- Lead Sponsor
- Bioiberica
- Brief Summary
The purpouse of this study is to determine the efficacy and safety of chondroitin sulphate conventional treatment in patients with both knee osteoarthritis and plaque psoriasis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 126
Inclusion Criteria
- Primary knee OA according to ACR criteria;
- OA of radiological stages 1 to 3 according to Kellgren-Lawrence;
- VAS of pain ≥30;
- PASI ≥ 5.
Exclusion Criteria
- Known allergy to chondroitin sulphate;
- Other bone and articular diseases such as chondrocalcinosis, Paget's disease, rheumatoid arthritis, psoriatic arthritis, acromegaly, hemochromatosis, Wilson's disease;
- Patients with skin conditions that could interfere in the clinical trial evaluation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Placebo - 1 Chondroitin sulphate Chondroitin sulphate
- Primary Outcome Measures
Name Time Method Huskisson Visual Analogue Scale Monthly Psoriasis Area and Severity Index Monthly
- Secondary Outcome Measures
Name Time Method Physician's Global Assessment of improvement Monthly Lequesne Index Monthly Use of rescue medication Monthly SF-36 Health Questionaire 3 months Overall Lession Severity Scale Monthly Histological assessment of skin biopsies 3 months Dermatology Life Quality Index Monthly Tolerability Monthly Adverse events Monthly
Trial Locations
- Locations (2)
Instituto Poal de Reumatología
🇪🇸Barcelona, Spain
Hospital del Mar
🇪🇸Barcelona, Spain